Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-4_04-cv-05429/USCOURTS-cand-4_04-cv-05429-46/pdf.json

Nature of Suit Code: 830
Nature of Suit: Patent
Cause of Action: 35:271 Patent Infringement

---

U

nite

d

States District C

o

u

rt

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

GENENTECH, INC., a Delaware

corporation, and TERCICA, INC., a

Delaware corporation,

Plaintiffs,

v.

INSMED INCORPORATED, a Virginia

corporation; CELTRIX PHARMACEUTICALS,

INC., a Delaware corporation; and

INSMED THERAPEUTIC PROTEINS, INC. a

Colorado Corporation,

Defendants.

 /

AND RELATED COUNTERCLAIMS.

 /

No. C 04-5429 CW

ORDER GRANTING

DEFENDANTS' 

MOTION IN LIMINE 2

Defendants Insmed, Inc., Celtrix Pharmaceuticals, Inc. and

Insmed Therapeutic Proteins, Inc. move, pursuant to their second

motion in limine, to exclude evidence, and testimony of Plaintiffs’

expert Dr. Charles Roberts, that Insmed’s DNA sequence encoding

IGFBP-3 infringes claim 20 of the ‘287 patent under the doctrine of

equivalents. 

The ‘287 patent’s prosecution history precludes Plaintiffs

from asserting a doctrine of equivalents argument with respect 

Case 4:04-cv-05429-CW Document 754 Filed 11/02/06 Page 1 of 2
U

nite

d

States District C

o

u

rt

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 2

to this claim. Therefore, Court GRANTS Defendants' motion in

limine 2. 

IT IS SO ORDERED.

Dated: 

CLAUDIA WILKEN

United States District Judge

Case 4:04-cv-05429-CW Document 754 Filed 11/02/06 Page 2 of 2